BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35395021)

  • 1. A randomized controlled trial comparing self-referred message to family-referred message promoting men's adherence to evidence-based guidelines on BRCA1/2 germline genetic testing: A registered study protocol.
    Petrocchi S; Ongaro G; Calvello M; Feroce I; Bonanni B; Pravettoni G
    PLoS One; 2022; 17(4):e0266327. PubMed ID: 35395021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychological Determinants of Men's Adherence to Cascade Screening for
    Ongaro G; Petrocchi S; Calvello M; Bonanni B; Feroce I; Pravettoni G
    Curr Oncol; 2022 Apr; 29(4):2490-2503. PubMed ID: 35448177
    [No Abstract]   [Full Text] [Related]  

  • 3. Investigating men's motivations to engage in genetic screening for BRCA1 and BRCA2 mutations.
    Annoni AM; Longhini C
    PLoS One; 2022; 17(3):e0265387. PubMed ID: 35303741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial.
    Kautz-Freimuth S; Redaèlli M; Isselhard A; Shukri A; Vodermaier A; Rhiem K; Schmutzler R; Stock S
    Trials; 2022 Feb; 23(1):157. PubMed ID: 35172875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care.
    Silverman TB; Vanegas A; Marte A; Mata J; Sin M; Ramirez JCR; Tsai WY; Crew KD; Kukafka R
    BMC Health Serv Res; 2018 Aug; 18(1):633. PubMed ID: 30103738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer.
    Derks-Smeets IA; Gietel-Habets JJ; Tibben A; Tjan-Heijnen VC; Meijer-Hoogeveen M; Geraedts JP; van Golde R; Gomez-Garcia E; van den Bogaart E; van Hooijdonk M; de Die-Smulders CE; van Osch LA
    Hum Reprod; 2014 May; 29(5):1103-12. PubMed ID: 24603131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.
    McVeigh TP; Sweeney KJ; Brennan DJ; McVeigh UM; Ward S; Strydom A; Seal S; Astbury K; Donnellan P; Higgins J; Keane M; Kerin MJ; Malone C; McGough P; McLaughlin R; O'Leary M; Rushe M; Barry MK; MacGregor G; Sugrue M; Yousif A; Al-Azawi D; Berkeley E; Boyle TJ; Connolly EM; Nolan C; Richardson E; Giffney C; Doyle SB; Broderick S; Boyd W; McVey R; Walsh T; Farrell M; Gallagher DJ; Rahman N; George AJ
    Fam Cancer; 2023 Apr; 22(2):135-149. PubMed ID: 36029389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
    Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users.
    Jacobs C; Pichert G; Harris J; Tucker K; Michie S
    Psychooncology; 2017 Nov; 26(11):1818-1824. PubMed ID: 28101941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
    Lee K; Yoo C; Kim KP; Park KJ; Chang HM; Kim TW; Lee JL; Lee W; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Shin SH; Hwang DW; Song KB; Lee JH; Kim SC; Ryoo BY
    Invest New Drugs; 2018 Feb; 36(1):163-169. PubMed ID: 28782087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using a Tailored Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer: Protocol for the DIALOGUE Study.
    Kim S; Aceti M; Baroutsou V; Bürki N; Caiata-Zufferey M; Cattaneo M; Chappuis PO; Ciorba FM; Graffeo-Galbiati R; Heinzelmann-Schwarz V; Jeong J; Jung MM; Kim SW; Kim J; Lim MC; Ming C; Monnerat C; Park HS; Park SH; Pedrazzani CA; Rabaglio M; Ryu JM; Saccilotto R; Wieser S; Zürrer-Härdi U; Katapodi MC
    JMIR Res Protoc; 2021 Jun; 10(6):e26264. PubMed ID: 34114954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
    Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
    J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
    Vos S; van Diest PJ; Moelans CB
    Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRACAVENIR - impact of a psychoeducational intervention on expectations and coping in young women (aged 18-30 years) exposed to a high familial breast/ovarian cancer risk: study protocol for a randomized controlled trial.
    Kwiatkowski F; Dessenne P; Laquet C; Daures JP; Gay-Bellile M; Bignon YJ
    Trials; 2016 Oct; 17(1):509. PubMed ID: 27769293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of structured endurance training and Mediterranean diet in BRCA1 and BRCA2 mutation carriers - an interventional randomized controlled multicenter trial (LIBRE-1).
    Kiechle M; Dukatz R; Yahiaoui-Doktor M; Berling A; Basrai M; Staiger V; Niederberger U; Marter N; Lammert J; Grill S; Pfeifer K; Rhiem K; Schmutzler RK; Laudes M; Siniatchkin M; Halle M; Bischoff SC; Engel C
    BMC Cancer; 2017 Nov; 17(1):752. PubMed ID: 29126396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.